Analyst Stock Recommendations For Destination Maternity Corporation (DEST), ChromaDex Corporation (CDXC)

Destination Maternity Corporation (NASDAQ:DEST) tinted gains of +1.36% (+0.04 points) to US$2.99. The volume of 0.07 Million shares climbed down over an trading activity of 68.68 Million shares. EPS ratio determined by looking at last 12 month figures is -0.57. Over the same time span, the stock marked US$6.84 as its best level and the lowest price reached was US$1.62. The corporation has a market cap of US$44.85 Million.

Destination Maternity Corporation (NASDAQ:DEST)’s earnings per share has been growing at a -19.8 percent rate over the past 5 year when average revenue increase was noted as -5.5 percent. The return on equity ratio or ROE stands at -47.4 percent while most common profitability ratio return on investment (ROI) was -9.5 percent. The company’s institutional ownership is monitored at 40.8 percent. The company’s net profit margin has achieved the current level of -4.5 percent and possesses 52 percent gross margin.

ChromaDex Corporation (NASDAQ:CDXC) is worth US$198.45 Million and has recently risen 0.28% to US$3.54. The latest exchange of 0.19 Million shares is below its average trading activity of 195.15 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$5.75 while the mean 12-month price target for the shares is US$8.75.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 5.8, and a price to sales ratio of 6.62. For the past 5 years, the company’s revenue has grown 12.8%, while the company’s earnings per share has grown 0.9%. With an institutional ownership near 17.6%, it carries an earnings per share ratio of -0.63.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.5.